Interface Analysis of the Complex between ERK2 and PTP-SL by Balasu, Mihaela C. et al.
Interface Analysis of the Complex between ERK2 and
PTP-SL
Mihaela C. Balasu
1,2, Laurentiu N. Spiridon
3, Simona Miron
4,5, Constantin T. Craescu
4,5, Axel J. Scheidig
6,
Andrei-Jose Petrescu
3, Stefan E. Szedlacsek
1*
1Department of Enzymology, Institute of Biochemistry, Bucharest, Romania, 2Department of Organic Chemistry , University POLITEHNICA, Bucharest, Romania,
3Department of Bioinformatics and Structural Biochemistry, Institute of Biochemistry, Bucharest, Romania, 4Institut Curie Centre de Recherche, Orsay, France, 5INSERM
U759, Orsay, France, 6Zoologisches Institut, Strukturbiologie/ZBM, Christian-Albrechts-Universita ¨t Kiel, Kiel, Germany
Abstract
The activity of ERK2, an essential component of MAP-kinase pathway, is under the strict control of various effector proteins.
Despite numerous efforts, no crystal structure of ERK2 complexed with such partners has been obtained so far. PTP-SL is a
major regulator of ERK2 activity. To investigate the ERK2–PTP-SL complex we used a combined method based on cross-
linking, MALDI-TOF analysis, isothermal titration calorimetry, molecular modeling and docking. Hence, new insights into the
stoichiometry, thermodynamics and interacting regions of the complex are obtained and a structural model of ERK2-PTP-SL
complex in a state consistent with PTP-SL phosphatase activity is developed incorporating all the experimental constraints
available at hand to date. According to this model, part of the N-terminal region of PTP-SL has propensity for intrinsic
disorder and becomes structured within the complex with ERK2. The proposed model accounts for the structural basis of
several experimental findings such as the complex-dissociating effect of ATP, or PTP-SL blocking effect on the ERK2 export
to the nucleus. A general observation emerging from this model is that regions involved in substrate binding in PTP-SL and
ERK2, respectively are interacting within the interface of the complex.
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Introduction
The MAP Kinase pathway represents one of the most important
signaling systems in eukaryotes. It controls a large variety of
fundamental cellular processes as proliferation, differentiation, cell
survival and apoptosis. Various extracellular stimuli, as growth
factors, cytokines, mitogens, environmental stress factors can
activate this pathway. Following MAP kinase pathway activation,
different cytosolic, membrane-bound or nuclear proteins are
expressed, which in turn regulate the transcription of specific genes
[1]. The best-studied representatives of the MAP kinase family are
ERK 1 and 2. Their activation involves phosphorylation of
Thr183 and Tyr185 on the activation loop, which promotes
reconstitution of the kinase active site [2]. Upon activation,
approximately half of ERK2 is translocated to the nucleus [3],
where it phosphorylates specific nuclear targets.
PTP-SL is a major regulator of ERK 1/2 MAP kinase activity.
There is an unusual reciprocal interaction within the complex
formed between these two proteins: ERK 1/2 phosphorylates Thr
253 of PTP-SL and PTP-SL dephosphorylates the regulatory
phosphotyrosine (pTyr 185) on the activation loop of ERK 1/2.
Dephosphorylation of pTyr 185 causes inactivation of ERK1/2
and its retention in the cytoplasm [4,5]. Also, association with
ERK1/2, phosphorylation of Thr 253 on PTP-SL, as well as
dephosphorylation of pTyr 185 on ERK1/2, are strictly
dependent on a novel, 16 amino acids long, Kinase Interaction
Motif (KIM). This motif is situated between residues 224–239 of
PTP-SL and is highly conserved among all members of the PTP-
SL sub-family. Within the KIM sequence, there is a PKA
consensus phosphorylation motif, Ser 231, which may be
phosphorylated and, thus, binding of ERK2 to PTP-SL is
impaired [6]. Consequently, the sub-family of PTP-SL seems to
control the activity of MAP kinases and mediates the crosstalk
between the MAP kinase cascade and the cAMP-dependent
kinases. The highly conserved KIM sequence helps binding of all
members of the KIM-containing PTPs (PTP-SL, PTPBR7, STEP
and HePTP). The sequence C-terminally adjacent to KIM,
termed kinase-specificity sequences (KISs), provides binding
specificity to ERK1/2 and p38. Thus, PTP-SL preferentially
binds ERK1/2 whereas STEP and HePTP selectively bind p38a
[7].
Crystal structures of inactive and active forms of ERK2 have
been reported [8,2]. Further crystallographic analysis of inactive
form of ERK2 in complex with a 16-mer KIM peptide derived
from hematopoietic PTP (HePTP) has shown that peptide binding
induces local and long-range conformational changes. The overall
aspect of peptide-bound ERK2 is rather similar to the phosphor-
ylated (active) form of ERK2 [9]. Interestingly, crystal structures of
other two MAPKs, p38 and JNK1, in complex with docking motif
(or D motif – a generical term used for KIM) peptides also
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unique to each enzyme [10,11]. Similarly, docking specificities
were demonstrated for the complexes of Fus3 – a yeast MAPK –
with specific peptides as well as for the complex of ERK2 with a
KIM peptide from MAP kinase phosphatase 3 [12,13].
Despite the relatively numerous reports concerning the docking
interaction between MAPKs and specific peptides, there are no
structural analyses extended to the interactions of sequences
proximal to the KIM region as well as to those involving the kinase
active sites. On the other hand it is obvious that the interaction
between a MAPK and a protein interactor is not limited to the
docking interaction. Specifically, no crystal structure of ERK2 in
complex with a substrate or other effector proteins, has been so far
reported. Consequently, any finding in this respect would be
particularly important in understanding the highly specific nature
of ERK2 interactions and the rigorous regulation of its activity.
Regarding the ERK2 - PTP-SL complex we previously provided
structural support for that the kinase action of ERK2 and the
phosphatase activity of PTP-SL involve two distinct conforma-
tional arrangements of the interacting partners [14]. Details of
these conformations and of how the transition between them takes
place are yet unknown. The overall structure of the N-terminal
region (aa 147–253) of cytosolic PTP-SL domain remains also
elusive as the largest PTP-SL catalytic region crystallized so far
was 254–549 [14] and the propensity for intrinsic disorder of the
147–253 region is very high. Given that the interacting KIM motif
is located here it is reasonable to presume that this region might
become structured only in the presence of ERK2.
In this report we investigate the ERK22PTP-SL complex by
isothermal titration calorimetry and chemical cross-linking com-
bined with MALDI-TOF. The resulting experimental data, along
with all the rest of structural data existing at hand in the literature
are introduced as imposed constraints to build a 3D-model of the
ERK22PTP-SL complex. The model is built starting from the
crystal structures of ERK2 and PTP-SL [12,14] by docking
combined with homology modeling and ab-initio modeling in
regions lacking template, followed by simulated annealing
optimization. This provides the contact interface in a conforma-
tion consistent with PTP-SL phosphatase activity. The final
refined version of the model accounts for the structural basis of
several reported observations, and also pinpoints novel character-
istics of the interaction interface for this physiologically important
complex.
Results
The overall strategy of the experiments was the following:
initially, optimal cross-linking reaction conditions for the complex
of ERK2 with PTP-SL were established, then the major cross-
linked product was isolated, digested with trypsin and the mixture
of peptides was analyzed by MALDI-TOF. In parallel, a control
experiment with the non-covalent complex (not treated with cross-
linker) was subjected to a similar treatment. Identification of mass
spectrometric signals corresponding to cross-linking of a peptide
from ERK2 with another one from PTP-SL grounded the
empirical constraints imposed in the ERK22PTP-SL model
building. A similar strategy was successfully applied for determi-
nation of structural models of other protein complexes and
multidomain proteins [15,16]
Cross-linking of ERK2 to PTP-SL
Two common cross-linking agents were tested: bis(sulfosuccini-
midyl) suberate (BS
3) - a homobifunctional agent reacting with
amino groups and providing a linker of 12 carbon atoms - and a
heterobifunctional agent producing zero length linker - 1-ethyl-3-
(3-dimethylaminopropyl) carbodiimide (EDC) (in presence of N-
hydroxysuccinimide (NHS)). All cross-linking experiments were
performed in absence of ATP in order to favor the conformations
of the complex which enable phosphatase activity of PTP-SL on
ERK2 and not the kinase activity of ERK2. Various conditions of
the cross-linking reaction were tested for both agents, by modifying
concentrations of cross-linker, complex concentration, incubation
time and temperature. EDC did not yield significant amount of
cross-linked product under any tested reaction conditions (data not
shown). Instead, BS
3 was found to be a relatively efficient cross-
linking agent of the ERK2–PTP-SL complex. BS
3 concentration
and incubation period were the most important parameters for the
cross-linking yield and composition of the cross-linked reaction
products (data not shown). In all situations, a minor band was
observed, corresponding to a cross-linked product of approxi-
mately 90 kDa as well as another electrophoretic band, corre-
sponding to the major product, of about 120–160 kDa. To analyze
whether the cross-linked products thus obtained are homo- or
heteromers, cross-linking reactions were performed in parallel,
using either individual ERK2 and PTP-SL proteins or the
complex of these two proteins. The complex produced a much
higher amount of cross-linked product than the individual proteins
(FIG. 1). However, homomers of PTP-SL (around 120 kDa) and
of ERK2 (mainly over 200 kDa), are also observed (theoretical
MWs of PTP-SL and ERK2 are 45623.15 and 42272.61,
respectively). Altogether, these results demonstrate that the ratio
of homomers in the cross-linked mixture is relatively low as
compared to the heteromers, thus proving that cross-linking is
strongly favored by the ERK2–PTP-SL complex formation. It
should be underlined that, for technical reasons, the inactive form
of ERK2 was used in cross-linking experiments, based on the
finding that both, active and inactive ERK2 form tight complexes
with PTP-SL [4]. One of the difficulties encountered in our
attempts to use the active (dephosphorylated) form of ERK2 in
cross-linking experiments was that it could not be completely
separated from monophosphorylated forms of ERK2; thus, the
heterogeneity of the ERK2 preparation would involve additional
complications in processing the cross-linking data.
Figure 1. BS
3 cross-linking reaction specificity. To compare
reaction specificity the cross-linking reaction with BS
3 was performed in
parallel with equimolar quantities of ERK2 (lane 1), PTP-SL (lane 2) and
ERK22PTP-SL complex (lane 3). Reaction mixtures were analysed by
SDS-PAGE (12,5%).
doi:10.1371/journal.pone.0005432.g001
ERK2-PTPSL Complex
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This step aims at isolating the main cross-linked product and,
also to eliminate the non-cross-linked products, the complex
molecules linked by disulfide bridges and the monomers. The
cross-linking reaction mixture obtained under optimal conditions
was applied and run through a Superdex 200 HR gel
chromatography column equilibrated with a buffer containing
both SDS and DTT. As shown in FIG. 2 three important peaks
were obtained. The evaluation of the MWs in selected fractions
was performed using SDS-PAGE combined with Zn-imidazole
staining, known to confer a more sensitive detection. The resulting
electrophoretic pattern shows that the first, minor peak, corre-
sponds to cross-linked products of MWs over 220 kDa, while the
second peak corresponds to the major cross-linked product at a
MW of 120–160 kDa, in agreement with estimations obtained
from SDS-PAGE shown in FIG. 2.
MALDI-TOF analysis of the cross-linked product
Direct analysis of the cross-linked product by MALDI-TOF
mass-spectrometry provided m/z values corresponding to PTP-SL
monomer and a charged ion peak at 91634.6 which may
correspond to a PTP-SL homodimer (FIG. 3A). Lack of signal
for the major cross-linked product at 120–160 kDa is not
surprising since high MW species sometimes are not detectable
by MALDI-TOF [17]. To obtain more information concerning
the amino acids at the interface, the purified complex correspond-
ing to the fractions with retention times 126–128 (FIG. 2) was
subjected to trypsinolysis and the resulting peptides were analyzed
by MALDI-TOF. In parallel, similar analyses were performed,
using the non-cross-linked complex. To identify those peptides
which were present in the cross-linked product but not in the non-
covalent complex, further comparative evaluation of the mass-
spectra thus obtained was performed. Initial processing of the
spectral data was performed using the Search-X-Link server
[18,19] leading to a list of potential attributions for the signals
detected in MALDI-TOF spectra for the cross-linked product.
Then, signals having similar m/z values in spectra corresponding
to non-cross-linked complex, were eliminated. Other signals,
corresponding to peptides not involved either in inter- or
intramolecular cross-linking, as well as peptides formed by trypsin
autolysis were also eliminated. Many of the peptides which should
theoretically result from ERK2 and PTP-SL hydrolysis were
identified in the mass-spectra. Analysis of mass-spectra obtained
on the basis of several independent experiments, evidenced four
molecular ions, having the m/z values 2221.75; 2573.88; 3155.87
and 3617.27, which are expected to be involved in the cross-
linking process (FIG. 3B). Figure 3C shows that these four signals
are missing in mass-spectra of the non-cross-linked complex,
Table 1 summarizes the theoretical and experimental masses of
peptides involved in intra- and intermolecular cross-linking of
different amino acidic residues within the complex, and their
potential assignments. Two main types of possible cross-linking
interactions may be observed: those involving only peptides from
PTP-SL and interactions between one peptide from PTP-SL and
one from ERK2. It should be noticed that lysine K310 of PTP-SL
is involved in three potential sequence assignments, all originating
from PTP-SL. Yet, the structure of PTP-SL (PDB code 1JLK)
shows that this residue is deeply buried in the core of the molecule
being rather inaccessible to the solvent (less than 10% accessibility
as measured with NACCESS). Thus, it is quite improbable that
the cross-linking agent BS
3 could have accessed this residue;
therefore, assignments involving K
310 of PTP-SL were eliminated.
In this way, the experimental mass of 3155.87 will be assigned to a
unique pair of cross-linked peptides. Specifically, this signal
corresponds to the cross-linking of the 390–401 fragment of
PTP-SL with the 193–205 fragment of ERK2. The first peptide
belongs to the surface exposed loop, linking the secondary
elements of PTP-SL, ß4 and ß7 [14]. As it contains two lysine
residues (K392 and K400) it is not possible to establish which of
these residues is directly involved in the cross-linking reaction
through BS
3. The second peptide involved in cross-linking
(fragment 193–205) is part of the linker L12 connecting
subdomains VIII and IX and is immediately following the P+1
binding area of ERK2 [8,2]. For the mass spectrometric signals at
m/z of 2221.75, 2573.88 and 3617.27, there are two alternative
assignments and, apparently, this fact generates a large number of
possible networks of interacting lysine residues. However, taking
into account that only six lysine residues of PTP-SL and three of
ERK2 are involved in cross-linking and that a given lysine residue
can only be involved in a single cross-linking interaction, it can be
inferred that only three alternatives are possible as concerning the
networks of the cross-linked lysine residues (FIG. 4). In order to
decide the most probable of cross-linking network alternatives
mentioned in FIG. 4 we used the unrefined docking model
obtained using crystal structures of PTP-SL and ERK2, by
positioning the phosphotyrosine of ERK2 lip into the active site of
PTP-SL (see also [14]). In this docking model we measured the
distance between the Cb atoms of K389
PTP-SL and its potential
Figure 2. Purification of major cross-linking product of the
ERK22PTP-SL complex. (A) Separation of the reaction products
formed by BS
3 cross-linking of the ERK22PTP-SL complex was
performed by size exclusion cromatography. (B) Fractions obtained
through the chromatographic separation of the cross-linking reaction
mixture (lanes 1–2, 4–6) were analysed by SDS-PAGE (12,5%). The non-
fractionated reaction mixture of BS
3 cross-linked ERK22PTP-SL complex
was applied on lane 3. Staining was performed with Zn-imidazole
reagent.
doi:10.1371/journal.pone.0005432.g002
ERK2-PTPSL Complex
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ERK2 involved both in alternative B and
alternative C. That distance was found to be 24 A ˚, significantly
higher than the 21.3 A ˚ limit corresponding to the maximally
allowed distance between Cb atoms of two lysines cross-linked with
BS
3 cross-linker. Therefore, this cross-linking interaction is highly
improbable and consequently, alternatives B and C can be
eliminated. The other two distances between lysine residues
involved in cross-linking according to alternative A, were found to
obey this criterion, thus supporting the proposed model. The
distance between K201
ERK2 and K400
PTP-SL was found to be
35.5 A ˚ as opposed to the 12.5 A ˚ distance between K201
ERK2 and
K392
PTP-SL thus suggesting that K201
ERK2 is cross-linked to
K392
PTP-SL and not to K400
PTP-SL. Thus, alternative D with
K201
ERK2 linked to K392
PTP-SL was found as the most probable
scheme of cross-linked residues and distance constraints obeying
this network were further used in model building.
Gel filtration experiments to evaluate the possibility of
homomolecular interactions in PTP-SL
According to the potential assignments given in Table 1,
homomolecular interactions may take place between PTP-SL
molecules. This hypothesis deserves a detailed analysis, since our
previous paper reported that the catalytic domain of PTP-SL is a
monomer, both in solution and in the crystal structure [14]. In
addition, the MW of 120–160, estimated in SDS-PAGE for the
complex between ERK2 and PTP-SL, raised the question whether
one of the partners within the complex is a dimer. To address this
question, we performed gel filtration experiments to determine the
MWs of the full cytoplasmic region of PTP-SL (used within the
cross-linking experiments), the N-terminally truncated form
containing the region 212–549, as well as the catalytically inactive
C480S mutant of the full cytoplasmic PTP-SL. Notably, besides
the catalytic domain the 212–549 truncated form still contains, the
KIM region which is essential for the interaction of PTP-SL with
ERK2. Interestingly, while this truncated form displayed an
apparent MW practically identical to the theoretical one, the full
cytoplasmic PTP-SL eluted with an apparent MW which is 1.74
times higher than the theoretical value (Table 2). A similar MW is
displayed by the C480S mutant of this protein. These findings
suggest that full cytoplasmic PTP-SL may be a dimer in solution
and that dimerization does not involve the active site cysteine
C480. The presence of a specific signal at the m/z value of 91634.6
in the mass spectrum of the cross-linked complex (FIG. 3A)
supports the idea that PTP-SL is a dimer which co-eluted with the
cross-linked complex. Full cytoplasmic PTP-SL (both the wild type
and the C480S mutant) forms complexes with ERK2 which also
display higher MWs than similar complexes based on the
truncated PTP-SL 212–549 construct. Considering that the
complex of non-truncated PTP-SL contains one ERK2 molecule
and two PTP-SL molecules, the experimentally determined MW
represents 84% of the theoretical value of this heterotrimer. Thus,
gel filtration experiments suggest that PTP-SL containing the full
Figure 3. MALDI-TOF spectrum of non-digested and trypsin digested, cross-linked ERK22PTP-SL complex. (A)The BS
3 cross-linked
complex was purified by size exclusion chromatography, concentrated, SDS removed and finally analysed in presence of sinapinic acid matrix.
Representative data for the digested cross-linked (B) and digested non-crosslinked (C) complex are shown. The magnified images a, b, c, d show the
four identified tryptic fragments which contain Lys-Lys cross-linked peptides.
doi:10.1371/journal.pone.0005432.g003
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PLoS ONE | www.plosone.org 4 May 2009 | Volume 4 | Issue 5 | e5432Figure 4. Potential networks of cross-linked lysine residues within the complex between ERK2 and PTP-SL. Processing the MALDI-TOF
data resulted from trypsinolysis of the cross-linked complex, three possible networks are revealed (denoted A,B and C). Arrows connect cross-linked
lysine residues from PTP-SL and ERK2. Dashed line arrow stands for: (i) an alternative involvement of K400 instead of K392 from PTP-SL in cross-linking
K201 from ERK2 and (ii) for a potential cross-link between K155 to K310 of PTP-SL, supporting the signal at m/z value of 2221.75. Most probable
network (see the text) of cross-links is illustrated in D.
doi:10.1371/journal.pone.0005432.g004
Table 1. Potential assignments for peptides obtained by tryptic digestion of cross-linked complex between PTP-SL and ERK2.
Observed mass
[M+H]+
Predicted mass
[M+H]+ Residue assignment Sequence assignment
PTP-SL ERK-2 PTP-SL ERK-2
2221.75 2221.48 301–312 - EIDIPRHGTK
310NR(2)
388–392 EK
389NEK(1)
2221.48 153–157 - QDK
155EK(1) -
301–312 EIDIPRHGTK
310NR(2)
2573.88 2573.97 153–157 147–162 QDK
155EK(1) DLK
149PSNLLLNTTCDLK
2573.97 388–392 147–162 EK
389NEK(1) DLK
149PSNLLLNTTCDLK
3155.87 3155.61 301–312 - EIDIPRHGTK
310NR(2) -
390–401 NEK
392CVLYWoxPEK
400R(2)
3155.71 390–401 193–205 NEK
392CVLYWPEK
400R(2) APEIMLNSK
201GYTK(1)
3617.27 3617.15 153–168 - QDK
155EKNQEIHLSPIAR(2) -
311–323 NRYK
314TILPNPLSR(2)
3617.31 313–329 329–340 YK
314TILPNPLSRVCLRPK(2) FDMELDDLPK
338EK(1)
Sequence data corresponding to peptides formed by intramolecular cross-linking of PTP-SL are written in italics. Lysine residues potentially involved in cross-linking
through BS
3 are underlined (numbering is mentioned as superscript). ‘‘Wox ’’denotes the oxidized form of tryptophan. ‘‘1’’ and ‘‘2’’ between parantheses refer to the
number of predicted missed cleavage sites.
doi:10.1371/journal.pone.0005432.t001
ERK2-PTPSL Complex
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mixture of monomers and dimers.
Calorimetric study of the ERK2/PTP-SL interaction
In order to get additional elements concerning the stoichiometry
of the complex, isothermal titration calorimetric (ITC) measure-
ments were also performed. Figure 5 shows the thermogram and
the binding isotherm corresponding to the titration of the inactive
mutant (containing active site Cys mutated to Ser) PTP-SL
m
(9 mM) by ERK2 (75 mM). The isotherm could be best fitted to a
single-site binding model, resulting in a stoichiometry of 1:1
(n=1.0660.005), an affinity of Ka=6.660.5610
6 M
21
(Kd=0.15 mM) and a reaction enthalpy DH=221.060.1 kcal/
mol. From the experimentally determined changes in enthalpy and
free energy upon the protein/protein interaction, one can
calculate the entropy contribution, TDS=211.5 kcal/mol. This
negative value means that the entropy term is unfavourable to the
interaction, likely due to a decreased conformational freedom of
the two proteins upon binding. The intermolecular interaction is
therefore driven by the enthalpic contribution. Similar results were
obtained when the wild type PTP-SL was used in the ITC
experiments.
Model building with experimental constraints
The overall model of PTP-SL - ERK2 complex was generated
in two steps. First, a model restricted to the regions (aa 254–549) of
PTP-SL and (aa 6–358) of ERK2 was generated, starting from the
existing crystal structures (PDB codes 1JLN and 2ERK,
respectively). This was named PECr. In the second step the PECr
model was used to build the rest of the PTP-SL cytoplasmic
domain (aa147–253). This was performed by ab-initio modeling
subjected to all the existing experimental constraints known to
date, including those derived from cross-linking experiments
(FIG. 6).
For building the PECr model, we proceeded as follows. The
PTP-1B complexed with a hexapeptide substrate containing
Table 2. Experimental and theoretical MWs of various PTP-SL constructs and of their complexes with ERK2.
Protein Predicted MW Observed MW Observed MW/Predicted MW
PTP-SL 212–549 38207.85 38259.1 1.00
PTP-SL 147–549 45623.15 79394.2 1.74
PTP-SL 147–549 (C480S) 45607.09 80722.5 1.77
Complex of PTP-SL 212–549 with ERK2 80480.45 60883.0 0.76
Complex of PTP-SL 147–549 with ERK2 87895.75 100154.2 1.14
Complex of PTP-SL 147–549 (C480S) with ERK2 87879.69 101829.9 1.16
Experimental MWs were calculated based on gel filtration experiments performed on a Superdex 200 HR analytical column run with mentioned protein preparations
under similar experimental conditions (see Materials and Methods).
doi:10.1371/journal.pone.0005432.t002
Figure 5. Isothermal Titration Calorimetry. The thermogram (upper panel) and the binding isotherm of the titration of PTP-SLm by ERK2 at
30uC. The thermogram was best fitted to a single site interaction model with a stoichiometry of 1:1.
doi:10.1371/journal.pone.0005432.g005
ERK2-PTPSL Complex
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template, both PTP-SL (aa 254–549) and the ‘new’ substrate, the
phosphorylated ERK2, were superimposed, in order to orient the
ERK2 in the phosphorylation region similarly to the hexapeptide
substrate in the template. This gives the triangulation of ERK2
with respect to PTP-SL. In order to find the best surface of
complementarity of the two protein surfaces and to eliminate all
steric conflicts, this structure was used as the starting point for
docking optimization using Rosetta Dock with constraints imposed
on the distances between the WPD loop of PTP-SL and
phosphotyrosine on the lip of ERK2 (residues W444
PTP-SL-
pY185
ERK2, P445
PTP-SL -pY185
ERK2 and D446
PTP-SL -
pY185
ERK-2). Rosetta Dock has the advantage of using explicit
flexibility of the side chains and was shown to be one of the best
ranked protein-protein docking methods, according to the CAPRI
evaluation [20]. The best docked structure was further refined by
simulated annealing, as described under ‘‘Experimental Proce-
dures’’. This produced a substantial stabilization of the PEC model
reflected in an additional .30% energy loss. The high stability of
refined PEC is also confirmed by MD simulation, which shows
that, for an overall 10 ns test run the rms deviation remains almost
flat, at very low levels of ,0.75 A ˚ for trace alpha carbons and
,1.0 A ˚ for all PEC atoms (FIG. 7). These values are at the lower
end of those usually observed in MD runs at 300 K started directly
from crystal structures [21]. This favorable result may be due to
several factors such as: the high content of secondary structures;
the good complementarity of the partners and the significant
decrease of exposed aminoacids in the complex state; and/or to
the MD-SA step used to refine PECr which brings the system into
a deep local minimum of the energy function. In addition, the
overall rms is entirely due to loop flexibility, with no long stretch or
domains showing any tendency to significantly deviate from the
initial structure in the two proteins (insets in FIG. 7).
It is worth noting here that the PTP-1B-hexapeptide complex
(1PTU) was a better template for PECr model than the CDK2-
KAP complex [22] for two main reasons. In the first place PTP-SL
is 67 aa larger in the N-terminal region than KAP, wich misses
helices a0, a1 and a19 from PTP-SL - and this introduces severe
clashes by superposition. The second reason is that ERK2 differs
signifficantly from CDK2, both functionally and structurally, in
their active site regions. For example, while the rms upstream and
downstream the active site between the two phosphatases is less
than 1 A ˚ for stretches of over 50aa, for only a 15aa around the
active site the rms is over 4 A ˚, with respect to both the
phosphorylated and dephosphorylated forms of ERK2.
The PECr model was then used as a starting point to generate
the missing region of the cytosolic part of PTP-SL (aa147–253), by
combined docking, ab-initio and homology modeling. At present,
there are no structural data on this region, as crystallization
attempts of the complex have failed so far. Interestingly, this is
consistent with predictions resulting from profiling the intrinsic
disorder propensity of PTP-SL by two distinct methods (FIG. 8A,
B), based either on scores derived from missing coordinates in high
resolution protein crystals [23], or pairwise energy estimates from
the amino acid composition [24]. Both methods indicate that the
PTP-SL region between aa147–250 has a clear tendency for
intrinsic disorder. This region might be therefore flexible and
consistent with multiple polypeptide paths in various states of the
protein. However, given that the interacting KIM motif is located
here it is reasonable to presume that the region might become
structured in the presence of ERK2. Modeling it in this state by ab-
initio techniques will yield only a low-resolution structure of rms
.5A ˚ as any prediction for proteins lacking homologues [25].
Nevertheless this low local accuracy can be improved by
constraints imposed by various experimental data. The first
experimental constraint is supplied by the crystal structure
Figure 6. The flowchart of ERK22PTP-SL complex model building.
doi:10.1371/journal.pone.0005432.g006
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derived from HePTP (PDB code 2GPH [9] ). The high sequence
homology between PTP-SL and HePTP, allowed modeling of this
stretch (aa223–253) by homology. The 15 amino acid KIM
peptide (aa224–239) was built by co-ordinate transfer and side
chain reconstruction while the connection to the PTP-SL (aa254–
549) region was built by random loop generation with constraints
imposed by the ends and the surface of PEC model, followed by
extensive simulated annealing. Finally, the rest of 77 amino acids
(aa147–223) had to be modeled by ab-initio procedures and to be
connected to the PTP-SL (aa224–549) model, both under the
docking constraints imposed by the PECr model surface and
distance constraints derived from cross-linking experiments and
polypeptide connection to the rest of the model. As multiple paths
are possible, a repertoire of over 100 ab-initio structures was
generated with Rosetta. These 3D structures were mapping
slightly different PTP-SL stretches of 78–90 amino acids
comprising the aa147–223 region, in order to maximize the 3D
structural diversity of the ab-initio models. Structures were clustered
according to their rms deviation and representatives of the top 5
largest clusters were used for docking with constraints imposed by
the PEC model surface, the connection at the PTP-SL aa223 end,
and the results of cross-linking experiments. From these, the best-
matching cross-linking constraints and PEC surface complemen-
tarity, was used to complete the overall model of PTP-SL (aa147–
549). This final version of PTP-SL (147–549)-ERK2 docking
model, named PECf was kept for further structure quality
assessment, representation and analysis (FIG. 9). From validation
with PROCHECK, the main-chain parameters match those of a
crystallographic structure of 2.0–2.5 A ˚ resolution, with a standard
deviation of omega angles slightly larger than expected, due
probably to CHARMm parametrization. Conversely, the side
chain parameters are all better than those of a standard 2.0 A ˚
structure. PROCHECK also shows that over 95% of the residues
are in favorable regions of the Ramachandran plot, above the
,90% limit generally accepted as a threshold for ‘good’
crystallographic models. In addition only a very low fraction of
the residues (0.8% in PTP-SL and 1.9% in ERK2) have torsion
angles in the fringes of ‘disallowed’ regions, indicating that the
structure meets the crystallographic standards at the end of all
modeling and simulation steps.
Intermolecular interaction energy analysis at the interface
between ERK2 and the low resolution model of the disordered
(aa147–253) region of PTP-SL, suggests that the top contribution
to the desolvation component of free energy is provided by PTP-
SL residues: V182, I205, T209, M220, L225, L235, L237 and
M239, while the top contribution to the electrostatic component is
provided also by PTP-SL: K155, V190, Q198, R228, R229, E246.
Particularly the KIM region seems to contribute significantly to
ERK2-PTP-SL complexation in this area of interface.
The PECf model shows that the residues L235, L237, M239 in
PTP-SL conserved among the KIM containing D-motif docking
peptides, are in van der Waals contact with L113, F127 and L155
residues from ERK2 and form a hydrophobic cluster. This cluster is
located near the KIM motif salt bridges, thus making the whole
region a strong stabilizing patch of the complex (FIG. 9B). We
analysed, the degree of conservation of these three residues within
the family of KIM-containing PTPs. We found that aminoacids
corresponding to L113 contain all bulky residues and 58.3% of them
arehydrophobic.AsconcerningthepositionsequivalenttoF127and
L155, the degree of conservation of the hydrophobic character is
100% and more than 90%, respectively. Thus, it can be considered
that the hydrophobic cluster delineated by L113, F127 and L155 is
conserved among the KIM-containing PTPs. Remarkably, this
patchisalsovicinalto theedge of theERK2ATP-binding pocket[8]
which,inthe present model,iscompletelycovered bytheN-terminal
part of PTP-SL (aa147–253 - Fig. 9). Thus PTP-SL and ATP may
compete in binding ERK2. This finding may explain why ATP is
able to dissociate the tight PTP-SL-ERK2 complex [5].
According to the model the PKA phosphorylation site S231
PTP-SL
is situated on the solvent exposed area of PTP-SL within the KIM
region. Although it is not oriented to the interface it is possible that
S231
PTP-SL phosphorylation will re-orient the side-chain during
conformational changes, thus impairing PTP-SL interaction with
ERK2 [6].
Our results also indicate that the KIS sequence - immediately
following the KIM region and contributing together with KIM to
differential binding of PTP-SL to ERK1/2 and p38 - is also
involved in specific interactions with ERK2. For instance, residues
S281
PTP-SL and S282
PTP-SL situated on the loop linking a19 and
a29 helices form hydrogen bonds with S264
ERK2 situated on the
loop a2L14, apparently involved in substrate recognition [8].
Notably, according to this model, the N-terminal half of the KIS
region coincides in fact with the flexible linker connecting the
KIM region and the catalytic domain of PTP-SL. While S264
ERK2
is relatively conserved among those MAP kinases where the similar
Figure 7. MD simulation RMSD and RMSF profiles. Over a 10 ns span the RMSD remains very low, below 0.75 A ˚ for trace alpha carbons of the
PECr complex. The RMSF profile over the sequence, shown in the inset, indicates that the RMSD is mainly due to the loop flexibility.
doi:10.1371/journal.pone.0005432.g007
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PTP-SL
are specific for PTP-SL but not for other KIM-containing PTPases.
Consequently, this interaction seems to contribute to the mentioned
specificity of PTP-SL interaction with ERK2.
Helix a29 of PTP-SL also plays an important role in interacting
ERK2. Thus, F289
PTP-SL - part of a29 – interacts with H230
ERK2
from L13 through stacking forces and hydrogen bond involving
peptide bond of F289
PTP-SL. The significance of H230
ERK2
located on L13 resides in its ‘‘strategic’’ position, right before
helix G which defines together with helix D, the substrate binding
groove of ERK2 [2]. Other residues on loop L13, like P224
ERK2,
P227
ERK2, K229
ERK2 and Y231
ERK2 also take part in binding
PTP-SL at the interface with ERK2. Except for the conserved
amino acid P224, the other residues which belong to this loop
seem to be rather specific for ERK2 but not for other MAP
kinases. On the other hand, the interacting partner residue
F289
PTP-SL is highly conserved. Experimental findings support the
fact that H230
ERK2 plays a role in substrate binding by ERK2.
Thus, H230N mutation, suggested to be a gain-of-function
mutation for ERK2 [26], was proved to produce partial resistance
to dephosphorylation by phosphatases from HEK293 cells [27].
The model shows that other structural regions of ERK2
responsible for substrate binding, are involved in interface
interactions as well. Residues of the loop L12 of ERK2,
encompassed between Y185
ERK2 and W190
ERK2 and termed
‘‘P+1’’ specificity region, represent such an example. One of the
most important of these residues is phosphotyrosine pY185
ERK2,
located on the phosphorylation lip of ERK2. According to our
model, its binding to the active site of PTP-SL is assisted by
hydrophobic (stacking) interactions with the highly conserved
residue Y313
PTP-SL which in turn is stabilized through hydropho-
bic forces between its aromatic ring and the aliphatic portion of
the side chain of R312
PTP-SL. This is an interesting finding,
because it confirms previous structural results obtained for the
complex of PTP-1B with peptide substrates. Thus, Y46 of PTP1B
(equivalent to Y313
PTP-SL) was found as part of the substrate
phosphotyrosine recognition loop [28]. The importance of this
residue for the catalytic activity of PTPs is also underlined by the
Figure 8. Intrinsic disorder propensity (IDP) of the PTP-SL sequence. IDP was calculated using DISOPRED (A) and IUPRED (B) methods.
doi:10.1371/journal.pone.0005432.g008
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PTP1B and of the
general aspartic acid of the catalytic WPD loop in the catalytically
inactive domain D2, confers robust activity in several PTPs [29–
31]. On the other hand R45 of PTP1B (equivalent to R312
PTP-SL)
is considered a putative substrate binding site [32]. Both R45
PTP1B
and Y46
PTP1B are conserved residues and belong to the
NXXKNRY motif, one of the ten conserved motifs which defines
the PTP family [32].
The orientation of a phosphorylated hexapeptide interacting
with PTP-SL (1PTU) was used as a key constraint in orienting
ERK2 with respect to PTP-SL. Thus, PECf conformation does
model the complex during ERK2 dephosphorylation. As phos-
phorylation and dephosphorylation require different conforma-
tions [14] and implicitly different interfaces, we examined whether
the presence of unphosphorylated form of ERK2 in the complex
might induce changes at the interaction interface. Replacing in
PECf the phosphorylated ERK2 with its dephosforylated form,
taken from 1ERK, results in significant clashes located in three
different areas of the interface. As previously reported [2], the
activation loop of ERK2 (aa172–189) is shifted extensively in
phosphorylated ERK2 adopting distinct conformation as com-
pared to the unphosphorylated form of ERK2. The major
consequence of this shift is that these two conformations of the
activation loop fall on opposite sides of the WPD catalytic loop of
PTP-SL (aa444–449). Therefore, it would be impossible a direct
switch by a dynamic trajectory between the two conformations
without a significant structural change of the WPD loop in PTP-
SL. By contrast, replacing phosphorylated ERK2 in PECf with its
dephosphorylated form taken from 2GPH (a structure in which
ERK2 is compexed with a KIM peptide analogue), results in
Figure 9. The PECf Model of the overall structure of ERK22PTP-SL complex in a conformation consistent with phosphatase activity.
(A) Network of crosslinks (FIG. 4) within the complex of ERK2 (orange) with PTP-SL (blue). The Lys
PTP-SL(yellow)-Lys
ERK2(green) pairs are connected by
orange links; (B) Representation of multiple interactions between the KIM containing segment from PTP-SL and ERK2. Cartoon representation: PTP-SL
main chain; surface representation: ERK2. The hydrophobic cluster is represented in white; the salt bridges are represented in magenta-yellow pairs.
The blue labels designate PTP-SL residues; the red labels designate ERK2 residues. (C) Spacefilling representation of the model of ERK22PTP-SL
complex with and without the segment 147–253
PTP-SL. Color coding: residues 254–549
PTP-SL in blue; residues 147–253
PTP-SL in dark magenta; residues
of ERK2 involved in ATP binding are colored in red whereas all other residues of the ERK2 chain are in orange.
doi:10.1371/journal.pone.0005432.g009
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the ERK2 activation loop being significantly lower - with both
structures falling on the same side of the WPD loop. This may
suggest that the ERK2 - PTP-SL contact in the KIM region
induces in ERK2 conformational changes similar to those
corresponding to the phosphorylation of ERK2 activation loop.
Discussion
Results of the cross-linking experiments, combined with SDS-
PAGE and MALDI-TOF analysis of the cross-linked products, as
well as the results of gel-filtration experiments on PTP-SL and its
complex with ERK2, support the idea that the complex is a
mixture of heterodimer and heterotrimer (composed of two PTP-
SL and one ERK-2 molecule). By contrast, according to the
isothermal calorimetric titration, the stoichiometry of the complex
is one PTP-SL to one ERK2 molecule. A possible explanation of
these contradictory results might be that the concentration of the
complex used in cross-linking and gel-filtration experiments was
much higher due to technical constraints, than that used in the
ITC experiment. Thus, it may be assumed that in fact an
equilibrium between 1:1 heterodimer and 2:1 heterotrimer forms
exists and high protein concentration shifts the equilibrium
towards the formation of heterotrimeric form.
The sub-micromolar range of the dissociation constant of the
heterodimer as obtained by calorimetric measurements (0.15 mM)
provides a quantitative support for the previously reported
experimental finding that this complex involves a very tight
interaction between the two proteins[5]. It cannot be ruled out
that, under in vivo conditions, the complex is in fact a larger entity.
Indeed, it has been shown that a member of the PTPBS family of
PTPs (human homologues of PTP-SL) forms, with oxysterol-
binding protein (OSBP), serine/threonine phosphatase PP2A and
cholesterol, a cca. 440 kDa oligomer which regulates phosphor-
ylation of ERK2 in HeLa cells [33]. Taking into account that
different residues of ERK2 are involved in interactions with
MEK1/2 kinase, PTP-SL and MKP-3 phosphatases [27] it can be
imagined that similarly, ERK2 state of phosphorylation is under
the coordinated control of both activating and inactivating
effectors in the same complex. Dimer state of PTP-SL as such
(which can be partially involved in the formation of the complex
with ERK2) suggests that dimerization may be part of a
mechanism that regulates its enzymatic activity and/or its
interaction with specific effectors. The cytoplasmic phosphatase
domains of other PTPs, were proved to form homo- and
heterodimers; for instance RPTPa forms homodimers [34] and
heterodimers [35] with the similar domains of the catalytically
inactive IA-2 and IA-2b PTPs, thus down-regulating its enzymatic
activity. According to our gel filtration experiments the presence of
the N-terminal sequence between L152-S211 is essential for
dimerization of PTP-SL. Notably, this sequence roughly repre-
sents the first half of the intrinsically disordered region
encompassed between aa147–253. Further mutational experi-
ments are necessary to identify the essential residues within this
sequence responsible for PTP-SL dimerization.
An interesting principle which seems to govern the interactions
between PTP-SL and ERK2, is that regions responsible for
substrate binding in individual proteins are reciprocally interacting
within the complex, as illustrated by the PECf model. Thus, the
KIM, KIS and NXXKNRY motifs from PTP-SL interact with
L16, a2L14 and L12 loops of ERK2, respectively, all involved in
binding of specific substrates. As concerning the interaction of the
L12 loop from ERK2 with KNRY motif of PTP-SL it confirms a
former hypothesis that the ERK2 catalyzed phosphorylation and
the PTP-SL catalyzed dephosphorylation require different con-
formations of the complex [14]. The model presented here reflects
the dephosphorylating action of PTP-SL. This shows that the
‘‘P+1’’ specificity region from L12 loop of ERK2 binds to
R312
PTP-SL and Y313
PTP-SL from the KNRY substrate recogni-
tion loop of PTP-SL, instead of P254
PTP-SL. Therefore, the
phosphorylating activity of ERK2 can be performed only by a
rearrangement of the conformation adopted by the complex, in
which T253
PTP-SL is directed to the active site of ERK2 and
consequently, binding of the neighbor residue P254
PTP-SL by the
‘‘P+1’’ specificity region on the L12 loop becomes possible. Given
that the presence of the KIM region of PTP-SL is essential for
complexing ERK2 [4], probably this rearrangement takes place
within the complex, while the KIM region is still bound to the
docking groove of ERK2. The intrinsic disorder profiles (FIG. 8)
show a high flexibility of the S240-P254 linker between the KIM
region and the catalytic domain of PTP-SL, supporting thus this
hypothesis. The ordered tertiary structure of the whole N-terminal
region of PTP-SL (aa147–253), as illustrated by our model,
suggests that this intrinsically disordered region of PTP-SL
becomes structured in interaction with ERK2. The calorimetric
data are in agreement with this interpretation, as the complex
formation involves loss of entropy. In other words, the interaction
with ERK2 leads to a decrease in flexibility of the N-terminus of
PTP-SL within the complex and implicitly, a decrease of entropy.
An important feature of the complex formation between PTP-
SL and ERK2 resides in the fact that PTP-SL blocks ERK2
translocation to the nucleus, due to its KIM-dependent binding of
ERK2 [5]. Data presented in this paper may provide a structural
explanation to this physiologically significant finding. Thus, it is
known that activated forms of ERK2 are dimers and dimerization
may promote nuclear localization of ERK2 [2,36]. It has been also
demonstrated that ERK2 dimer formation is mediated by a
hydrophobic zipper, located on the C-terminal L16 loop [2]. On
the other hand, according to our model, PTP-SL interaction with
ERK2 involves the same loop L16. Therefore, it can be assumed
that the interaction between the phosphorylated ERK2 dimer and
PTP-SL leads to disruption of the ERK2 dimer, due to
competition for the same L16 region. Consequently, as soon as
the ERK2 dimer is disassembled, its translocation to the nucleus
may be blocked and ERK2 is retained in the cytoplasm.
PTPRR is a human homologue of PTP-SL and there are reports
indicating its involvement in nerve growth factor signaling, thus
representing potential target in the therapy of neurodegenerative
processes, like Alzheimer disease [37,38]. Thus, the down-regulating
effect of KIM-containing PTPs on ERK2 and on other MAPK
activities may play an important role in this respect. Data presented in
this paper, as well as the published structure of PTPRR [39], may
contribute to a more in-depth understanding of the mechanism of this
important regulatory process. In addition, it should be emphasized
that the combination of chemical cross-linking with mass spectro-
metric measurements can be used for the interface analysis of any
other protein complexes where only the structures of the partners are
known. The reliability of this technique was alsodemonstrated for the
complex between the signal recognition particle and its receptor
where the resulting model was in good agreement with crystal
structure of the complex [40].
Materials and Methods
Plasmid construction, Mutagenesis, Proteins expression
and Purification
The cDNA corresponding to the full cytoplasmic region of PTP-
SL (aa147–549) and its abridged form (aa212–549) were inserted
ERK2-PTPSL Complex
PLoS ONE | www.plosone.org 11 May 2009 | Volume 4 | Issue 5 | e5432into the pGEX-4T1 expression vector (GE Healthcare) and the
resulting recombinant plasmids were subsequently used to
transform DH5a host cells. cDNA of ERK2 was cloned into the
pHAT2 expression vector [41] using as host BL21(DE3) cells for
the expression of the corresponding protein. The C480S mutant of
PTP-SL was obtained by site-directed mutagenesis using Quick-
Change kit (Stratagene) according to the manufacturer’s protocol.
All PTP-SL constructs were purified according to the procedure
previously described for the catalytic domain of PTP-SL [14].
ERK2 was expressed in pHAT2 as a fusion protein with an N-
terminal 66His-tag. The fusion protein was initially purified by
affinity chromatography on a HiTrap Chelating column (GE
Healthcare) and then by ion exchange chromatography on a
Mono Q column (GE Healthcare). The complexes between PTP-
SL constructs and ERK2 were prepared by mixing the purified
PTP-SL construct with a slight molecular excess of purified ERK2
protein, with short incubation on ice and finally separation of the
complex from the excess of ERK2 by size exclusion chromatog-
raphy.
Cross-linking with BS
3
BS
3 was obtained from Pierce (Rockford, USA). The PTP-SL-
ERK2 complex, in 100 mM HEPES buffer, pH=7.5 with
300 mM NaCl, was incubated with freshly prepared BS
3 solution.
This solution contains BS
3 dissolved in 5 mM citrate buffer,
pH=5. Reaction conditions were varied in the following ranges:
0.1–1 mM cross-linking reagent, 2.2–5.54 mg/ml complex, 30–
120 min. reaction time and temperature between 0uC and 25uC.
The cross-linking reaction was terminated by the addition of 1/6
volume of 300 mM Tris buffer, pH=7.5. The cross-linking
reactions of PTP-SL and ERK2 with BS
3 were performed under
the same optimal conditions as in the case of the complex.
Gel electrophoresis
Gel electrophoretic separation of cross-linked products and non-
cross-linked molecules was performed using 12% polyacrylamide
gels under denaturating conditions [42]. MW markers were
obtained from Bio-Rad. The protein bands were visualized with
Coomassie Blue reagent [42] and Zn/imidazole reagent [43].
Size exclusion chromatography
To purify the cross-linking conjugate gel filtration was carried
out at room temperature with a Superdex 200 HR column 2.2/58.
The column was equilibrated with gel filtration buffer: 10 mM
Hepes, 150 mM NaCl, 0.1 mM EDTA, 5 mM DTT, 1% SDS,
pH=7.5. A volume of 200 ml cross-linking mixture was incubated
for 5 min with 40 ml gel filtration buffer at room temperature,
then boiled for 5 min. The boiled sample was centrifuged at
14,000 rpm, 10 min. 220 ml of mixture was applied on the
column. Fractions of 500 ml were collected at a flow rate of
0.4 ml/min. A Superdex 200 HR 10/30 analytical column was
used in the size exclusion chromatography experiments, to
calculate MWs of the PTP-SL forms: 212–549, 147–549, 147–
549(C480S) alone and of the various forms of their complexes with
ERK2. The gel filtration buffer was the same as previously
mentioned but without SDS. For each run 100 ml sample was
applied on the column. The flow rate was established at 0.5 ml/
min. Gel Filtration Standard (BioRad) was used for MW
calibration.
ITC measurements
Thermodynamic parameters of molecular interactions between
ERK2 and PTP-SL at 30uC were investigated by ITC using a
MicroCal MCS instrument (MicroCal Inc., Northampton, MA). A
PTP-SL solution (8–10 mM) in the calorimeter cell (1.337 mL) was
titrated by ERK2 (75–100 mM) using automatic injections of 8–
10 mL. The first injection of 2 ml was ignored in the final data
analysis. Integration of the peaks corresponding to each injection
and correction for the baseline were done using Origin-based
software provided by the manufacturer. Fitting of the data to an
interaction model results in the stoichiometry (n), equilibrium
binding constant (Ka) and enthalpy of complex formation (DH).
The experimental data allow calculation of the free energy change
(DG) and of the entropy term (TDS), according to the classical
thermodynamic formulae: DG=2RT6ln Ka and
DG=DH2TDS. All the experiments were repeated twice, and
give similar results. The control experiment, consisting in injecting
an ERK2 solution into the buffer, shows that the heat of dilution is
negligible. The raw calorimetric data were fitted to a simple model
with a single type binding site. Three parameters are thus
optimized by minimizing the mean square distance between
experimental and calculated points. For the stoichiometry n, the
optimized value was n=1.06 with the standard error 0.005,
reflecting a great confidence for the 1:1 stoichiometry. In fact, for
affinity values larger than 10
6 M
21 the isothermal binding curve
has a clear sigmoidal shape with the inflection point indicating the
stoichiometry value.
MALDI-TOF MS and analysis of MS data
The cross-linked complex purified by size exclusion chroma-
tography (pooled fractions corresponding to 120–160 kDa) was
first precipitated with methanol/chloroform according to a
reported procedure [44] in order to remove SDS and to increase
the protein concentration. Cross-linked PTP-SL, cross-linked
ERK2, non-cross-linked PTP-SL and non-cross-linked ERK2,
were processed similarly. The pellets thus obtained were then
digested with 0.25 mg/ml bovine b-trypsin (sequencing grade,
Roche) during 14 h in a digestion buffer containing 100 mM
NH4HCO3, pH 8.2 with 10 mM CaCl2. After centrifugation, the
supernatants were directly used for MALDI-TOF analysis. The
saturated a-cyano-4-hydroxycinnamic matrix was prepared in
acetonitrile/aqueous TFA 0.4% (3:2), mixed with digested samples
and applied to a stainless-steel probe plate. Spectra were acquired
with a Voyager DE-PRO workstation, using a delayed extraction,
linear mode. Mass accuracies were obtained with external
calibration. All reported masses are averaged values. The purified,
cross-linked complex was also directly analyzed by MALDI-TOF,
using sinapinic acid as matrix. The MALDI-TOF spectral data
corresponding to the tryptic peptide mixture were introduced in
Search-X-links program [18,19] and analyzed (mass accuracies of
#120 ppm).
Modeling
Homology modeling was performed with Insight II software
package from Accelrys. The Homology module was used for
coordinate transfer and loop generation. Local simulated anneal-
ing and energy minimization during modeling steps were
performed via the Discover module with cvff force field. - Instrinsic
disorder assignment was performed with DISOPRED [23] and
IUPRED [24]. - Ab initio modeling was performed using
HMMSTR/Rosetta [25] which combines the Monte Carlo
fragment insertion for protein tertiary structure prediction
(ROSETTA) with the I-sites library of sequence structure motifs
and the HMMSTR model for local secondary and supersecondary
structure. - Docking was performed with InsightII, RosettaDock
[45] and CHARMm [46]. InsightII was used to generate the
starting coordinates of the complex. Optimization of the binding
ERK2-PTPSL Complex
PLoS ONE | www.plosone.org 12 May 2009 | Volume 4 | Issue 5 | e5432geometry was performed with RosettaDock with distance
constraints. Structure refinement of the complex was performed
using the following molecular dynamics simulated annealing (MD-
SA) procedure: the MD-SA was started at 1000 K, after an initial
1 ps stage of fast heating the system was cooled down to 10 K at a
constant rate of 5 K/0.3 ps. In order to avoid structure distortion
during the high temperature steps absolute positional harmonic
restraints with a force constant of 50 kcal/molA ˚ 2 were imposed on
a-carbons of aminoacids along the polypeptide chain found in
definite secondary structure states (H, I, E). Simulated annealing
was followed by extensive constraint-free energy minimization.
- In both MD-SA steps and model stability tests MD simulation was
carried with CHARMm using CHARMM27 force field [47]. MD
runs were performed in explicit solvent using TIP3P water model,
with periodic boundary conditions in a 77.6693.1671.4 A ˚ 3 box,
at constant temperature (NVT dynamics) at 300 K and RMSD
was measured with VMD. Intermolecular free energy calculations
were performed with FastContact [48]. Finally the model was
evaluated using PROCHECK V.3.4.4 [49] in order to verify if the
quality of structure at the end of the modeling procedures meets
the crystallographic standards.
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